论文部分内容阅读
目的:探讨在肺腺癌患者中联合应用CEA检测和SELDI蛋白芯片技术诊断的价值。方法:应用免疫化学发光技术检测69例肺腺癌患者及71例健康对照者血清标志CEA;同时应用表面增强激光解吸电离飞行时间质谱技术(SELDI-TOF)和CM10芯片检测该血清,经BiomarkerWizard软件分析,结合临床病理资料分析两种手段的联合诊断价值。结果:免疫化学发光法检测CEA的敏感度为62.319%(43/69),特异度为92.958%(66/71);SELDI-TOF-MS技术检测的敏感度为88.406%(61/69),特异度为68.182%(15/22);两者联合检测的敏感度为82.609%(57/69),特异度为92.958%(66/71)。结论:免疫化学发光法检测CEA和SELDI-TOF-MS技术联合检测蛋白标志比单用免疫化学发光法检测CEA能提高对肺腺癌诊断的敏感度。但与单独使用SELDI-TOF-MS技术相比,两者联合检测的敏感度无明显提高。
Objective: To explore the value of combined CEA detection and SELDI protein chip diagnosis in patients with lung adenocarcinoma. Methods: Serum CEA was detected in 69 patients with lung adenocarcinoma and 71 healthy controls by using immunochemiluminescence technique. The serum was detected by surface-enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDI-TOF) and CM10 chip. BiomarkerWizard software Analysis, combined with clinical and pathological data analysis of the two methods of joint diagnostic value. Results: The sensitivity of CEA was 62.319% (43/69) and specificity was 92.958% (66/71) respectively. The sensitivity of SELDI-TOF-MS was 88.406% (61/69) The specificity was 68.182% (15/22). The sensitivity of combined detection was 82.609% (57/69) and the specificity was 92.958% (66/71). CONCLUSION: CEA and SELDI-TOF-MS combined with immunohistochemical detection of CEA can increase the diagnostic sensitivity to lung adenocarcinoma compared with immunochemiluminescence. However, there was no significant increase in the combined detection of SELDI-TOF-MS compared with alone.